TY - JOUR
T1 - Novel pharmacological treatments for generalized anxiety disorder
T2 - Pediatric considerations
AU - Sonmez, A. Irem
AU - Almorsy, Ammar
AU - Ramsey, Laura B.
AU - Strawn, Jeffrey R.
AU - Croarkin, Paul E.
N1 - Funding Information:
We thank Anosha Zanjani for her expertise and assistance with the creation of Figures 1 and 2 . We thank Danielle Gerberi for her help with the literature search. The preparation of this manuscript was supported by the National Institutes of Health (NIH) under awards R01 MH113700 (P. E. C.) and R01 HD098757 (J. R. S.). The content of this publication is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The supporters had no role in the literature review, interpretation, or publication.
Publisher Copyright:
© 2020 Wiley Periodicals LLC
PY - 2020/8/1
Y1 - 2020/8/1
N2 - Background: Pediatric anxiety disorders such as generalized anxiety disorder (GAD) are common, impairing, and often undertreated. Moreover, many youth do not respond to standard, evidence-based psychosocial or psychopharmacologic treatment. An increased understanding of the gamma-aminobutyric acid (GABA) and glutamate neurotransmitter systems has created opportunities for novel intervention development for pediatric GAD. Methods: This narrative review examines potential candidates for pediatric GAD: eszopiclone, riluzole, eglumegad (LY354740), pimavanserin, agomelatine. Results: The pharmacology, preclinical data, clinical trial findings and known side effects of eszopiclone, riluzole, eglumegad (LY354740), pimavanserin, agomelatine, are reviewed, particularly with regard to their potential therapeutic relevance to pediatric GAD. Conclusion: Notwithstanding numerous challenges, some of these agents represent potential candidate drugs for pediatric GAD. Further treatment development studies of agomelatine, eszopiclone, pimavanserin and riluzole for pediatric GAD also have the prospect of informing the understanding of GABAergic and glutamatergic function across development.
AB - Background: Pediatric anxiety disorders such as generalized anxiety disorder (GAD) are common, impairing, and often undertreated. Moreover, many youth do not respond to standard, evidence-based psychosocial or psychopharmacologic treatment. An increased understanding of the gamma-aminobutyric acid (GABA) and glutamate neurotransmitter systems has created opportunities for novel intervention development for pediatric GAD. Methods: This narrative review examines potential candidates for pediatric GAD: eszopiclone, riluzole, eglumegad (LY354740), pimavanserin, agomelatine. Results: The pharmacology, preclinical data, clinical trial findings and known side effects of eszopiclone, riluzole, eglumegad (LY354740), pimavanserin, agomelatine, are reviewed, particularly with regard to their potential therapeutic relevance to pediatric GAD. Conclusion: Notwithstanding numerous challenges, some of these agents represent potential candidate drugs for pediatric GAD. Further treatment development studies of agomelatine, eszopiclone, pimavanserin and riluzole for pediatric GAD also have the prospect of informing the understanding of GABAergic and glutamatergic function across development.
KW - agomelatine
KW - anxiety
KW - drug development
KW - eglumegad (LY354740)
KW - eszopiclone
KW - generalized anxiety disorder
KW - pediatric
KW - pimavanserin
KW - riluzole
UR - http://www.scopus.com/inward/record.url?scp=85085022152&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85085022152&partnerID=8YFLogxK
U2 - 10.1002/da.23038
DO - 10.1002/da.23038
M3 - Review article
C2 - 32419335
AN - SCOPUS:85085022152
SN - 1091-4269
VL - 37
SP - 747
EP - 759
JO - Depression and Anxiety
JF - Depression and Anxiety
IS - 8
ER -